Roivant Sciences Ltd
Ownership
Ownership Structure
Who owns Roivant Sciences Ltd (ROIV)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 80.4% of the shares are freely tradable; institutional investors hold 75.9%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| FMR Inc | 10.80 | 77,981,253 | +18.5 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 7.18 | 51,828,325 | -11.2 | 03/31/2026 |
| BlackRock Inc | 6.13 | 44,254,260 | +7.5 | 03/31/2026 |
| Qvt Financial LP | 3.28 | 23,723,074 | -5.7 | 06/30/2026 |
| UBS Group AG | 3.13 | 22,619,472 | +23.0 | 03/31/2026 |
| Vanguard Capital Management, LLC | 2.86 | 20,680,572 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 2.75 | 19,838,698 | +0.0 | 03/31/2026 |
| State Street Corp | 2.24 | 16,186,613 | -6.8 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Fidelity Growth Compy Commingled Pl S | 4.20 | 30,317,677 | +1.3 | 07/31/2026 |
| Fidelity Growth Company Fund | 3.18 | 22,974,528 | +1.5 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Sukhatme Mayukh | President & CIO | 18,630,739 | 741,503,412 $ | Aug 21, 2026 | direct |
| Gold Daniel Allen | Director | 8,960,761 | 356,638,288 $ | Sep 10, 2026 | direct |
| Venker Eric | President & Immunovant CEO | 1,599,154 | 63,646,329 $ | Aug 28, 2026 | direct |
| Pulik Richard | CFO | 271,810 | 10,818,038 $ | Aug 20, 2026 | direct |
| Oren Ilan | Director | 118,626 | 4,721,315 $ | Sep 10, 2026 | direct |
| Momtazee James C | Director | 106,905 | 4,254,819 $ | Sep 10, 2026 | direct |
| Fitzgerald Meghan | Director | 36,108 | 1,437,098 $ | Sep 15, 2026 | direct |
| Epperly Melissa B, | Director | 9,900 | 394,020 $ | Sep 15, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 15, 2026 | Epperly Melissa B, | Director | Sell | 600 | 40.38 | 24,228 |
| Sep 15, 2026 | Epperly Melissa B, | Director | Sell | 4,338 | 39.65 | 172,002 |
| Sep 15, 2026 | Fitzgerald Meghan | Director | Sell | 400 | 40.45 | 16,180 |
| Sep 15, 2026 | Fitzgerald Meghan | Director | Sell | 4,712 | 39.68 | 186,972 |
| Sep 10, 2026 | Epperly Melissa B, | Director | Other | 2,179 | 40.94 | 89,208 |
| Sep 10, 2026 | Oren Ilan | Director | Other | 2,378 | 40.94 | 97,355 |
| Sep 10, 2026 | Fitzgerald Meghan | Director | Other | 1,743 | 40.94 | 71,358 |
| Sep 10, 2026 | Momtazee James C | Director | Other | 2,905 | 40.94 | 118,931 |
| Sep 10, 2026 | Gold Daniel Allen | Director | Other | 5,133 | 40.94 | 210,145 |
| Sep 8, 2026 | Fitzgerald Meghan | Director | Sell | 20,000 | 39.90 | 798,000 |
| Sep 8, 2026 | Fitzgerald Meghan | Director | Other | 20,000 | 8.80 | 176,000 |
| Aug 28, 2026 | Venker Eric | President & Immunovant CEO | Sell | 33,818 | 36.44 | 1,232,328 |
| Aug 28, 2026 | Venker Eric | President & Immunovant CEO | Sell | 166,182 | 35.63 | 5,921,065 |
| Aug 28, 2026 | Venker Eric | President & Immunovant CEO | Other | 200,000 | 3.85 | 770,000 |
| Aug 21, 2026 | Sukhatme Mayukh | President & CIO | Sell | 144,756 | 36.48 | 5,280,699 |
| Aug 21, 2026 | Sukhatme Mayukh | President & CIO | Other | 144,756 | 3.85 | 557,311 |
| Aug 20, 2026 | Pulik Richard | CFO | Other | 5,749 | 36.84 | 211,793 |
| Aug 20, 2026 | Venker Eric | President & Immunovant CEO | Other | 13,909 | 36.84 | 512,408 |
| Aug 20, 2026 | Sukhatme Mayukh | President & CIO | Sell | 17,519 | 37.30 | 653,459 |
| Aug 20, 2026 | Sukhatme Mayukh | President & CIO | Other | 17,519 | 3.85 | 67,448 |
| Aug 19, 2026 | Sukhatme Mayukh | President & CIO | Sell | 172,899 | 37.17 | 6,426,656 |
| Aug 19, 2026 | Sukhatme Mayukh | President & CIO | Other | 172,899 | 3.85 | 665,661 |
| Aug 18, 2026 | Sukhatme Mayukh | President & CIO | Sell | 31,801 | 37.18 | 1,182,361 |
| Aug 18, 2026 | Sukhatme Mayukh | President & CIO | Other | 31,801 | 3.85 | 122,434 |
| Aug 18, 2026 | Sukhatme Mayukh | President & CIO | Sell | 105,141 | 36.59 | 3,847,109 |
| Aug 18, 2026 | Sukhatme Mayukh | President & CIO | Other | 105,141 | 3.85 | 404,793 |
| Aug 17, 2026 | Sukhatme Mayukh | President & CIO | Sell | 284,707 | 36.25 | 10,320,629 |
| Aug 17, 2026 | Sukhatme Mayukh | President & CIO | Other | 284,707 | 3.85 | 1,096,122 |
| Aug 14, 2026 | Sukhatme Mayukh | President & CIO | Sell | 243,177 | 36.23 | 8,810,303 |
| Aug 14, 2026 | Sukhatme Mayukh | President & CIO | Other | 243,177 | 3.85 | 936,231 |
| Jul 27, 2026 | Venker Eric | President & Immunovant CEO | Sell | 200,000 | 34.95 | 6,990,000 |
| Jul 27, 2026 | Venker Eric | President & Immunovant CEO | Other | 200,000 | 3.85 | 770,000 |
| Jul 17, 2026 | Momtazee James C | Director | Other | 405 | 0.00 | – |
| Jul 17, 2026 | Epperly Melissa B, | Director | Other | 543 | 0.00 | – |
| Jul 17, 2026 | Oren Ilan | Director | Other | 775 | 0.00 | – |
| Apr 20, 2026 | Eric Venker | CEO | Sell | 200,000 | 29.59 | 5,918,000 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.